Drug trials in neuroblastoma: cyclophosphamide (NSC-26271) alone; vincristine (NSC-67574) plus cyclophosphamide; 6-mercaptopurine (NSC-755) plus 6-methylmercaptopurine riboside (NSC-40774); and cytosine arabinoside (NSC-63878) alone.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use*; D004341:Drug Evaluation; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006801:Humans; D007223:Infant; D007288:Inosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015122:Mercaptopurine / Q000009:adverse effects / Q000627:therapeutic use*; D009362:Neoplasm Metastasis; D009447:Neuroblastoma / Q000188:drug therapy*; D012075:Remission, Spontaneous; D013440:Sulfides / Q000009:adverse effects / Q000627:therapeutic use; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D013440:Sulfides; D003561:Cytarabine; D007288:Inosine; D014750:Vincristine; D003520:Cyclophosphamide; D015122:Mercaptopurine